Cell-Penetrating Peptide Fusion Proteins for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional protein therapeutics face challenges in penetrating cell membranes, resulting in low efficacy due to poor cell penetration and stability, which limits their therapeutic effectiveness.
Innovation Solution
Development of a therapeutic molecule comprising a cell-penetrating peptide derived from Antennapedia, a dominant-negative protein, and a chemical linker, which facilitates the transport of pharmaceutically active substances across cell membranes, enhancing therapeutic delivery and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional protein therapeutics are used, then the therapeutic molecule can be synthesized, but the cell membrane penetration is poor resulting in low efficacy
Solution Approach 1:
The patent merges a cell-penetrating peptide (CPP) domain with a therapeutic protein to create a fusion protein. The CPP domain (derived from Antennapedia) facilitates cell membrane penetration while the therapeutic protein provides the desired biological activity. This combining of functions resolves the contradiction by enabling both membrane penetration and therapeutic efficacy simultaneously.
Solution Approach 2:
The cell-penetrating peptide acts as an intermediary carrier that facilitates the transport of the therapeutic protein across the cell membrane. The CPP serves as a mediator between the extracellular environment and the intracellular therapeutic cargo, solving the penetration problem without compromising the therapeutic function.
2Productivity
If the therapeutic protein is delivered into cells, then the therapeutic mechanism can be activated, but the protein stability inside cells is reduced
Solution Approach 1:
The patent employs chemical modifications and peptide variants that change the structural parameters of the fusion protein to enhance stability. Specific modifications include optimizing the CPP sequence, adding stabilizing mutations, and using crosslinking agents to rigidify the protein structure, thereby maintaining stability while preserving therapeutic activity.
Solution Approach 2:
The fusion protein creates a composite structure combining the cell-penetrating peptide domain with the therapeutic protein. This composite architecture allows the CPP portion to facilitate entry while the therapeutic protein portion maintains its functional stability through proper folding and structural constraints within the fusion context.
3Productivity
If cell-penetrating peptides are used to deliver cargo, then the delivery efficiency is improved, but the immunogenicity increases
Solution Approach 1:
The patent applies local quality modification by selectively modifying specific regions of the CPP sequence while maintaining others. Variants are created with specific amino acid substitutions in the CPP domain that reduce immunogenicity in certain regions while preserving the membrane penetration function in critical regions. This localized optimization resolves the contradiction between delivery efficiency and immunogenicity.
Data Source
AI summary
The present invention relates to diagnostic and therapeutic molecules comprising derivatives of a cell-penetrating protein and any appropriate dominant-negative peptide and/or protein.